170921-49-0

Basic information

• Product Name: N-BENZYL-4-AMINO-PIPERIDINE-4-CARBOXAMIDE
• Synonyms: N-BENZYL-4-AMINO-PIPERIDINE-4-CARBOXAMIDE;4-Amino-1-benzylpiperidine-4-carboxamide;4-PiperidinecarboxaMide, 4-aMino-1-(phenylMethyl)-;4-AMino-N-benzylpiperidine-4-carboxaMide
• CAS NO: 170921-49-0
• Molecular Formula: C₁₃H₁₉N₃O
• Molecular Weight: 233.31
• Mol File: 170921-49-0.mol

Chemical Properties

• Boiling Point: 416.97°C at 760 mmHg
• Flash Point: 205.976°C
• Appearance: /
• Density: 1.165g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.588
• Storage Temp.: Room temperature.
• PKA: 15.84±0.20(Predicted)
• CAS DataBase Reference: N-BENZYL-4-AMINO-PIPERIDINE-4-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZYL-4-AMINO-PIPERIDINE-4-CARBOXAMIDE(170921-49-0)
• EPA Substance Registry System: N-BENZYL-4-AMINO-PIPERIDINE-4-CARBOXAMIDE(170921-49-0)

Safety Data

• Hazardous Substances Data: 170921-49-0(Hazardous Substances Data)

Usage

Uses

As the specific applications of N-Benzyl-4-amino-piperidine-4-carboxamide are not well-documented, it is difficult to provide a comprehensive list of its uses. However, given its classification under the piperidines group, it may have potential applications in various industries, such as pharmaceuticals, chemical research, or material science. Further research and development would be necessary to determine its specific uses and benefits in these fields.

InChI:InChI=1/C13H19N3O/c14-12(17)13(15)6-8-16(9-7-13)10-11-4-2-1-3-5-11/h1-5H,6-10,15H2,(H2,14,17)

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 773837-37-9 sodium cyanide 
• 136624-42-5 4-amino-1-benzylpiperidine-4-carbonitrile 

Downstream Products

• 170921-52-5 8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1,3,8-triaza-spiro[4.5]decan-4-one 
• 1029432-53-8 C₁₈H₂₇N₃O₃ 
• 1017789-30-8 8-benzyl-1,3,8-triazaspiro[4.5]dec-2-en-4-one 
• 1383575-61-8 8-(4,6-dimethylpyrimidin-2-yl)-3-((1-tosyl-1H-indol-3-yl)methyl)-1,3,8-triazaspiro[4.5]decan-4-one 
• 1579514-66-1 8-benzyl-2-(4-bromophenyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one 
• 1579514-68-3 (S)-tert-butyl 3-((8-benzyl-2-(4-bromophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-3-yl)methyl)pyrrolidine-1-carboxylate 
• 1579514-72-9 (R)-8-benzyl-2-(4-bromophenyl)-3-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one 
• 1579514-59-2 (R)-2-(4-(1H-indol-5-yl)phenyl)-8-benzyl-3-((1-(cyclopropanecarbonyl) pyrrolidin-3-yl)methyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one 
• 1579514-80-9 (R)-2-(4-bromophenyl)-3-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one 
• 1579515-54-0 (R)-8-acetyl-2-(4-bromophenyl)-3-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one 
• 1579514-64-9 1-benzyl-4-(4-bromobenzamido)piperidine-4-carboxamide 
• 170921-48-9 8-benzyl-1,3,8-triazaspiro<4.5>decan-4-one 

Relevant articles and documents

Design and Synthesis of Fsp3-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening

The exploration of innovative chemical space is a critical step in the early phases of drug discovery. Bis-spirocyclic frameworks occur in natural products and other biologically relevant metabolites and show attractive features, such as molecular compactness, structural complexity, and three-dimensional character. A concise approach to the synthesis of bis-spirocyclic-based compound libraries starting from readily available commercial reagents and robust chemical transformations has been developed. A number of novel bis-spirocyclic scaffold examples, as implemented in the European Lead Factory project, is presented.

IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.

IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.

Discovery of a highly selective PLD2 inhibitor (ML395): A new probe with improved physiochemical properties and broad-spectrum antiviral activity against influenza strains

Further chemical optimization of the halopemide-derived family of dual phospholipase D1/2 (PLD1/2) inhibitors afforded ML395 (VU0468809), a potent, >80-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50>30 000 nm; cellular PLD2, IC50=360 nm). Moreover, ML395 possesses an attractive in vitro DMPK profile, improved physiochemical properties, ancillary pharmacology (Eurofins Panel) cleaner than any other reported PLD inhibitor, and has been found to possess interesting activity as an antiviral agent in cellular assays against a range of influenza strains (H1, H3, H5 and H7).

Spiperone: Influence of spiro ring substituents on 5-HT(2A) serotonin receptor binding

Spiperone (1) is a widely used pharmacological tool that acts as a potent dopamine D2, serotonin 5-HT(1A), and serotonin 5-HT(2A) antagonist. Although spiperone also binds at 5-HT(2C) receptors, it is one of the very few agents that display som